BrachyDOSE

BrachyDOSE is a Lithuanian medtech company addressing the critical need for precision in cancer radiotherapy, specifically within the brachytherapy segment. Founded in January 2024 by CEO Neringa Šeperienė and Rimas Šeperys, the Kaunas-based startup is developing a quality control tool to improve the accuracy and safety of radiation treatments. Šeperienė’s background, which includes degrees in applied and medical physics and a PhD in materials engineering from Kaunas University of Technology, provides the foundational expertise for the company's direction. The team also comprises specialists in medical device engineering, data analytics, and medical oncologists.

The company's core offering is a system that integrates hardware and software to provide real-time, data-driven feedback during radiotherapy procedures. The hardware consists of a disposable, flexible tube-shaped sensor that is placed near the tumor before treatment. This sensor measures the actual radiation dose delivered in real-time. After the procedure, a scanner retrieves the data, which is then analyzed by the system's software. This software employs a machine learning-based algorithm to compare the delivered dose against the prescribed treatment plan, identify discrepancies, and predict the likelihood of potential injuries. This process provides clinicians with immediate, actionable data to support decision-making and prevent patient injuries from over or under-dosing.

BrachyDOSE operates in the global radiation therapy quality assurance market, targeting oncology hospitals and clinics that perform brachytherapy for cancers such as breast, cervical, and prostate. Its business model appears to be centered on the sale of the hardware system (scanner) and the recurring revenue from the disposable, single-use sensors. The company is currently in a pre-commercial phase, focusing on securing regulatory approval to enter the European market. A recent seed funding round of €554,000, led by Coinvest Capital with participation from BSV Ventures, LitBAN, and EstBAN, is being used to finalize the CE and Medical Device Regulation (MDR) certification processes. The company has already established collaborations with the National Cancer Centre of Vilnius University Hospital Santaros Clinics and the Oncology Hospital of the Lithuanian University of Health Sciences to test and validate its technology.

Keywords: brachytherapy, radiotherapy quality assurance, medical device, cancer treatment, dosimetry, real-time dose measurement, radiation oncology, medtech, dose verification, treatment planning system, Neringa Šeperienė, medical physics, injury prediction algorithm, disposable medical sensor, CE/MDR certification, Coinvest Capital, BSV Ventures, oncology technology, patient safety, radiation dose monitoring